1. Home
  2. UBX vs SHFS Comparison

UBX vs SHFS Comparison

Compare UBX & SHFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UBX
  • SHFS
  • Stock Information
  • Founded
  • UBX 2009
  • SHFS 2015
  • Country
  • UBX United States
  • SHFS United States
  • Employees
  • UBX N/A
  • SHFS N/A
  • Industry
  • UBX Biotechnology: Pharmaceutical Preparations
  • SHFS Finance: Consumer Services
  • Sector
  • UBX Health Care
  • SHFS Finance
  • Exchange
  • UBX Nasdaq
  • SHFS Nasdaq
  • Market Cap
  • UBX 29.2M
  • SHFS 20.8M
  • IPO Year
  • UBX 2018
  • SHFS N/A
  • Fundamental
  • Price
  • UBX $2.22
  • SHFS $0.50
  • Analyst Decision
  • UBX Strong Buy
  • SHFS
  • Analyst Count
  • UBX 2
  • SHFS 0
  • Target Price
  • UBX $7.00
  • SHFS N/A
  • AVG Volume (30 Days)
  • UBX 483.8K
  • SHFS 345.8K
  • Earning Date
  • UBX 11-04-2024
  • SHFS 11-12-2024
  • Dividend Yield
  • UBX N/A
  • SHFS N/A
  • EPS Growth
  • UBX N/A
  • SHFS N/A
  • EPS
  • UBX N/A
  • SHFS 0.10
  • Revenue
  • UBX N/A
  • SHFS $15,658,629.00
  • Revenue This Year
  • UBX N/A
  • SHFS N/A
  • Revenue Next Year
  • UBX $33.62
  • SHFS N/A
  • P/E Ratio
  • UBX N/A
  • SHFS $4.82
  • Revenue Growth
  • UBX N/A
  • SHFS 7.78
  • 52 Week Low
  • UBX $0.94
  • SHFS $0.30
  • 52 Week High
  • UBX $3.10
  • SHFS $1.10
  • Technical
  • Relative Strength Index (RSI)
  • UBX 61.12
  • SHFS 65.58
  • Support Level
  • UBX $2.02
  • SHFS $0.37
  • Resistance Level
  • UBX $2.42
  • SHFS $0.53
  • Average True Range (ATR)
  • UBX 0.31
  • SHFS 0.04
  • MACD
  • UBX 0.01
  • SHFS 0.01
  • Stochastic Oscillator
  • UBX 39.61
  • SHFS 77.78

About UBX Unity Biotechnology Inc.

Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.

About SHFS SHF Holdings Inc.

SHF Holdings Inc is a financial services provider to cannabis-related businesses. It offers reliable access to banking solutions for cannabis, hemp, CBD, and ancillary operators, making communities safer, driving growth in local economies, and fostering long-term partnerships. The group, through its financial institution clients, implements accountability, transparency, monitoring, reporting, and risk mitigation measures while meeting Bank Secrecy Act obligations in line with FinCEN guidance on cannabis-related businesses. Its services include Program Management Support, Customer Generation, Ongoing Program Auditing, and Compliance Monitoring among others.

Share on Social Networks: